No profile data available.
Synairgen plc (SYGGF) is a healthcare company in the antiviral pharmaceuticals industry, based in Southampton, United Kingdom, with about 34 full-time employees.
It reported revenue of $0 for fiscal year 2023, and net income of -$8.41 million. Its market capitalization was $110,266 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
Synairgen reported $0 in revenue for fiscal year 2023.
$110,266 as of October 8, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include NanoViricides, Inc. (NNVC), Cocrystal Pharma, Inc. (COCP), GeoVax Labs, Inc. (GOVX).